Medication Administration and Efficacy for Gastrointestinal Disorders

Dosage and Administration

The American Gastroenterological Association recommends that plecanatide and linaclotide be taken on an empty stomach, with linaclotide administered at least 30 minutes before the first meal of the day, while plecanatide can be taken with or without food 1
The recommended dosage for adults with Chronic Idiopathic Constipation (CIC) or Irritable Bowel Syndrome with Constipation (IBS-C) is 3 mg once daily for plecanatide, and 290 mcg once daily for linaclotide 1, 2
The recommended dosing for Linaclotide is as follows:
Condition Age Dosage
IBS-C Adults 290 mcg once daily
CIC Adults 72 mcg or 145 mcg once daily
Functional constipation Children 6-17 years 72 mcg once daily

Linaclotide is considered the most efficacious secretagogue available for IBS-C according to the British Society of Gastroenterology, and has demonstrated significant efficacy in clinical trials for both IBS-C and chronic constipation, with improvements in abdominal pain, stool consistency, and complete spontaneous bowel movements 4, 2, 1
Both medications improve complete spontaneous bowel movements (CSBMs), spontaneous bowel movements (SBMs), stool consistency, and quality of life measures 1
Linaclotide significantly improves the FDA composite endpoint for IBS-C with a number needed to treat (NNT) of 5.1, with 33.7% of linaclotide-treated patients being FDA endpoint responders vs. 13.9% of placebo-treated patients (p<0.0001), and reduces abdominal pain, with 48.9% of patients reporting ≥30% reduction vs. 34.5% with placebo, as reported in clinical trials 3

Both medications are contraindicated in patients with known or suspected mechanical GI obstruction 1
Linaclotide should be used with caution in elderly patients who may be more susceptible to diarrhea-induced dehydration, as recommended by the American Geriatrics Society and the American Gastroenterological Association 1, 2
Patients should be monitored for signs of dehydration, including decreased urination, dry mouth, dizziness, and increased thirst, and the monitoring protocol should include assessing bowel movement frequency and consistency, and watching for signs of dehydration or electrolyte disturbances, as suggested by the American Gastroenterological Association 5, 1

The most common adverse effect of linaclotide is diarrhea, occurring in approximately 16-20% of patients, which is generally mild to moderate in severity but may require dose reduction or discontinuation in severe cases, as reported in clinical trials 2, 4, 1
Diarrhea may lead to discontinuation in approximately 4% of patients receiving linaclotide compared to 0.3% with placebo 2
Linaclotide (Linzess) and senna can be safely taken together to treat constipation, as they work through different mechanisms, according to the American College of Cardiology and other gastroenterology guidelines 6, 3, 1

Linaclotide costs approximately $523/month, and prucalopride costs approximately $563/month, as suggested by the American Gastroenterological Association 1
Coverage varies significantly between insurance providers and specific plans, and many plans may require prior authorization, documentation of failed first-line therapies, and specialist referral documentation, which can affect access to Constella, but pharmaceutical manufacturers sometimes offer patient assistance programs to improve access, as reported by the American Gastroenterological Association 4, 7